Wednesday, September 16, 2026Latest filing Sep 14, 2026

NVO Congressional Stock Trades

Novo Nordisk A/S Common Stock (NVO)

Last disclosed trade Mar 30

Every disclosed trade in NVO by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.

Sample · the intelligence layer

Coldpine signal scoreA 0-1 composite from four weighted factors: disclosure speed, trade size, cluster activity (multiple members buying the same name), and the member’s track record. ≥ 0.65 is the high-conviction tier; ≥ 0.50 is moderate. Trades from trust-managed members are penalized (× 0.2 multiplier). It’s research, not a recommendation.

Marjorie Taylor Greene · Bought $NVO · Aug 19 · $15K–$50K

0.70HIGH
Disclosure speedx 0.251.00
Trade sizex 0.250.50
Cluster activityx 0.150.30

1 other member traded this name in the same window.

Track recordx 0.350.80

Coldpine’s read

Greene's purchase of Novo Nordisk, maker of GLP-1 drugs Ozempic and Wegovy, was disclosed within one day, a fast turnaround that means the market may not have absorbed the filing. At least one other member traded the same name in the same direction within 30 days, indicating some cluster activity. The $15,001–$50,000 range is consistent with her typical individual equity purchases.

Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →

Follow $NVO

Get notified when any member of Congress trades $NVO. Free, no card, no spam.

Follow free →
38
Disclosed trades
27
Buys
11
Sells
8
Members trading

The record on $NVO

Coldpine has parsed 38 disclosed trades in $NVO by 8 members of Congress, drawn from 21 periodic transaction reports dated Oct 7, 2022 through Mar 30, 2026. That is 37 trades from House members and 1 trade from senators, filed 10 by Democrats and 28 by Republicans.

Of the 38 trades with a known filing lag, 3 were reported more than 45 days after the trade date, outside the window the STOCK Act sets. The median lag was 22 days. The longest was 763 days: a $NVO purchase by Byron Donalds dated Oct 7, 2022, disclosed Nov 8, 2024. How late filing is measured across all of Congress is in the late-filers study.

31 of the 35 trades that list an account holder (89%) were reported under a spouse, dependent child, or joint account rather than the member directly.

Michael T. McCaul filed the most $NVO purchases (10), and Rohit Khanna the most sales (6).

Activity peaked in 2024 with 15 trades. The busiest single month was August 2025, when 2 different members disclosed $NVO trades.

Across the 25 purchases Coldpine can price, $NVO moved +1.47% on average between the trade date and the disclosure date, against +2.10% for the S&P 500 over the same windows. The stock was higher at disclosure than at the trade in 52% of those purchases. That is a record of what already happened, not a forecast. Method: what stocks do before Congress discloses.

Members who trade NVO

Recent disclosed trades in NVO

DateMemberTypeAmount
Mar 30Alan Armstrong(OK)buy$15K–$50K
Oct 15Marjorie Taylor Greene(GA)buy$1K–$15K
Sep 11Lisa McClain(MI)buy$1K–$15K
Aug 28Marjorie Taylor Greene(GA)buy$1K–$15K
Aug 19Marjorie Taylor Greene(GA)buy$15K–$50K
Aug 4Scott Franklin(FL)buy$1K–$15K
Aug 4Scott Franklin(FL)buy$1K–$15K
Aug 4Scott Franklin(FL)buy$1K–$15K
Aug 4Scott Franklin(FL)buy$15K–$50K
May 8Laurel Lee(FL)sell$1K–$15K
Mar 27Scott Franklin(FL)buy$15K–$50K
Mar 27Scott Franklin(FL)buy$1K–$15K
Mar 20Byron Donalds(FL)sell$1K–$15K
Mar 20Byron Donalds(FL)sell$1K–$15K
Dec 23Michael T. McCaul(TX)buy$15K–$50K
Dec 23Michael T. McCaul(TX)buy$15K–$50K
Oct 31Michael T. McCaul(TX)buy$15K–$50K
Oct 31Michael T. McCaul(TX)buy$1K–$15K
Aug 26Michael T. McCaul(TX)sell$1K–$15K
Aug 26Michael T. McCaul(TX)sell$1K–$15K

Showing 20 of 38 disclosed trades.

Sign up free for the full history, signal scores, the price-vs-trades chart, and Coldpine's read (the AI narrative on each trade).

Create a free account

Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →